Jörg Sievers

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2019 · 212 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

Michael Aboud, Richard Kaplan, Johannes Lombaard et al. · The Lancet Infectious Diseases · 2019 · 198 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Novel Inhibitors of Bacterial Cytokinesis Identified by a Cell-based Antibiotic Screening Assay

Neil R. Stokes, Jörg Sievers, Stephanie Barker et al. · Journal of Biological Chemistry · 2005 · 109 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +13

Decreased plasma phospholipid concentrations and increased acid sphingomyelinase activity are accurate biomarkers for community-acquired pneumonia

Haroon Arshad, Juan Carlos López Alfonso, Raimo Franke et al. · Journal of Translational Medicine · 2019 · 70 citations · Full text

Life Sciences, Biochemistry, Infectious Diseases +11